Cancer stem cell antigen-based vaccines: The preferred strategy for active specific immunotherapy of metastatic melanoma?

Expert Opinion on Biological Therapy

Volumn 13, Issue 5, 2013, Pages 643-656

  Dillman, Robert O ^a   Cornforth, Andrew N ^b   Nistor, Gabriel ^b  

^a Hoag Hospital   (United States)

^b California Stem Cell Inc   (United States)

Author keywords

Active specific immunotherapy; Cancer stem cells; Melanoma; Therapeutic cancer vaccines

Indexed keywords

2,4 DINITROPHENOL; ALPHA INTERFERON; BACTERIAL ANTIGEN; BCG VACCINE; CANCER VACCINE; CYCLOPHOSPHAMIDE; DACARBAZINE; GANGLIOSIDE; INTERLEUKIN 2; IPILIMUMAB; TEMOZOLOMIDE; VEMURAFENIB; VIRUS ANTIGEN;

CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER STAGING; CANCER STEM CELL; CAPILLARY LEAK SYNDROME; CELL PROLIFERATION; CYTOTOXIC T LYMPHOCYTE; DERMATITIS; DRUG MEGADOSE; ENDOCRINE DISEASE; ENTEROCOLITIS; FATIGUE; FLU LIKE SYNDROME; HUMAN; IMMUNE RESPONSE; LIVER DISEASE; LOW DRUG DOSE; LYMPH NODE METASTASIS; LYMPHOKINE ACTIVATED KILLER CELL; METASTATIC MELANOMA; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TUMOR ASSOCIATED LEUKOCYTE;

ADJUVANTS, IMMUNOLOGIC; ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL PROLIFERATION; HUMANS; IMMUNOTHERAPY; MELANOMA; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS;

EID: 84876029350     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.759556     Document Type: Review

References (85)

1. Siegel R, Naishadhma D, Jamal A. Cancer Statistics, 2012. Cancer J Clin 2012;62:10-29
2. Balch CM, Gershenwald JE, Soong S-J, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-206
3. Dillman RO, Barth NM, VanderMolen LA, et al. Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic melanoma? Cancer Biother Radiopharm 2012;27:337-43
4. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16
5. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366:707-14
6. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23
7. Robert C, Thomas LO, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated melanoma. N Engl J Med 2011;364:17-26
8. Finn OJ. Cancer immunology. N Engl J Med 2008;358:2704-15
9. Dillman RO. Cancer immunotherapy. Cancer Biother Radiopharm 2011;26:1-64
10. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54
11. Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity anti-PD-L1 antibody inpatients with advanced cancer. N Engl J Med 2012;366:2455-65
12. Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immuotherapy. Clin Cancer Res 2011;17:4550-7
13. Livingston PO, Wong GY, Adluri S, et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994;12:1036-44
14. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2- KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/ C509801. J Clin Oncol 2001;19:2370-80
15. Lawson DH, Lee SJ, Tarhini AA, et al. E4697: phase III cooperative group study of yeast-derived granulocyte macrophage colony-stimulating factor (GM-CSF) versus placebo as adjuvant treatment of patients with completely resected stage II-IV melanoma [abstract 8504]. J Clin Oncol 2010;28(Suppl):15s
16. Schwartzentruber DJ, Lawson DH, Richards JM, et al. Gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011;364:2119-27
17. Wallack MK, Sivanandham M, Balch CM, et al. A phase III randomized, double-blind multiinstitutional trial of vaccinia melanomaoncolysate-active specific immunotherapy for patients with stage II melanoma. Cancer 1995;75:34-42
18. Wallack MK, Sivanandham M, Balch CM, et al. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg 1998;187:69-77
19. Bystryn JC, Zeleniuch-Jacquotte A, Oratz R, et al. Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine. Clin Cancer Res 2001;7:1882-7
20. Sondak VK, Liu PY, Tuthill RJ, et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol 2002;20:2058-66
21. Hersey P, Coates AS, McCarthy WH, et al. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. J Clin Oncol 2002;20:4181-90
22. Mitchell MS, Abrams J, Thompson JA, et al. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon alfa-2b compared with high-dose interferon alfa-2b for resected stage III cutaneous melanoma. J Clin Oncol 2007;25:2078-85
23. Morton DL, Mozzillo N, Thompson JF, et al. An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites [abstract 8508]. J Clin Oncol 2007;25:474s
24. Weide B, Zelba H, Derhovanessian E, et al. Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. J Clin Oncol 2012;1835-41
25. Senzer NN, Kaufman HL, Amatruda T, et al. Phase II clinical trial of a grnaulocyte-macrophage colonystimulating factor-endoding, second-generation oncyloytic Herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009;27:5763-71
26. Clive KS, Tyler Ja, Clifton GT, et al. Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental? Expert Rev Vaccines 2010;9:519-25
27. Spitler LE, Grossbard ML, Ernstoff MS, et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colonystimulating factor. J Clin Oncol 2000;18:1614-21
28. Spitler LE, Weber RW, Allen RE, et al. Recombinant human granulocyte-macrophage colonystimulating factor (GM-CSF, sargramostim) administered for 3 years as adjuvant therapy of stages II(T4), III, and IV melanoma. J Immunother 2009;32:632-7
29. Slingluff CL Jr, Petroni GR, Yamshchikov GV, et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colonystimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 2003;21:4016-26
30. Weber J, Sondak VK, Scotland R, et al. Granulocyte-macrophage- colonystimulating factor added to a multipeptide vaccine for resected stage II melanoma. Cancer 2003;97:186-200
31. Steinman R. The dendritic cell system and its role in immunogenicity. Ann Rev Immunol 1991;9:271-96
32. Hart DNJ. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 1997;90:3245-87
33. Nencioni A, Grunebach F, Schmidt SM, et al. The use of dendritic cells in cancer immunotherapy. Crit Rev Oncol Hematol 2008;65:191-9
34. Eubel J, Enk A. Dendritic cell vaccination as a treatment modality for melanoma. Expert Rev Anticancer Ther 2009;9:1631-42
35. Banchereau J, Ueno H, Dhodapkar M, et al. Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type 1 interferon. J Immunother 2005;28:505-16
36. Schadendorf D, Ugurel S, Schuler-Thurner B, et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase II trial of the DC study group of the DeCOG. Annal Oncol 2006;17:563-70
37. Lesterhuis WJ, Schreibelt G, Scharenborg NM, et al. Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used. Cancer Immunol Immunother 2011;60:249-60
38. Wilgenhof S, Van Nuffel AM, Corthals J, et al. Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma. J Immunother 2011;34:448-56
39. Lopez MN, Pereda C, Segal G, et al. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing cells. J Clin Oncol 2009;27:945-52
40. Ribas A, Camacho LH, Lee SM, et al. Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma. J Transl Med 2010;8:89
41. Trepiakas R, Berntsen A, Hadrup SR, et al. Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial. Cytother 2010;12:721-34
42. Hersey P, Menzies SW, Halliday GM, et al. Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma. Cancer Immunol Immunother 2004;53:125-34
43. Hersey P, Halliday GM, Farrelly ML, et al. Phase I/II study of treatment with matured dendritic cells with or without low dose IL-2 in patients with disseminated melanoma. Cancer Immunol Immunother 2008;57:1039-51
44. O'Rourke MG, Johnson M, Lanagan C, et al. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendrtitic cell vaccine. Cancer Immunol Immunother 2003;52:387-95
45. O'Rourke MG, Johnson MK, Lanagan CM, et al. Dendritic cell immunotherapy for stage IV melanoma. Melanoma Res 2007;17:316-22
46. Redman BG, Chang AE, Whitfield J, et al. Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma. J Immunother 2008;31:591-8
47. Ridolfi L, Petrini M, Fiammenghi L, et al. Dendritic cell-based vaccine in advanced melanoma: update of clinical outcome. Melanoma Res 2011;21:524-9
48. Parmiani G, Castelli C, Dalerba P, et al. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst 2002;94:805-18
49. Kawakami Y, Dang N, Wang X, et al. Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma. J Immunother 2000;23:17-27
50. Brinkman JA, Fausch SC, Weber JS, Kast WM. Peptide-based vaccines for cancer immunotherapy. Expert Opin Biol Ther 2004;4:181-98
51. Berd D. M-Vax: an autologous, hapten-modified vaccine for human cancer. Expert Rev Vaccines 2004;3:521-7
52. Berd D, Maguire HC Jr, McCue P, et al. treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. J Clin Oncol 1990;8:1858-67
53. Berd D, Maguire HC Jr, Schuchter LM, et al. Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J Clin Oncol 1997;15:2359-70
54. Testori A, Richards J, Whitman E, et al. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol 2008;26:955-62
55. Kyrgidis A, Tzellos T-G, Triaridis S. Melanoma: stem cells, sun exposure and hallmarks for carcinogenesis, molecular concepts and future clinical implications. J Carcinogen 2010;9:3
56. Nguyen LV, Vanner R, Dirks P, Eaves CJ. Cancer stem cells: an evolving concept. Nat Rev Cancer 2012;12:133-43
57. Clarke MF, Fuller M. Stem cells and cancer: two faces of eve. Cell 2006;124:1111-15
58. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994;367:645-8
59. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008;8:755-68
60. Maugeri-Sacca M, Vigneri P, De Maria R. Cancer stem cells and chemosensitivity. Clin Cancer Res 2011;17:4942-7
61. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100:3983-8
62. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-60
63. Girouard SD, Murphy GF. Melanoma stem cells: not rare, but well done. Lab Invest 2011;91:647-64
64. Preuss KD, Zwick C, Bormann C, et al. Analysis of the B-cell repertoire against antigens expressed by human neoplasms. Immunol Rev 2002;188:43-50
65. Yang F, Yang XF. New concepts in tumor antigens: their significance in future immunotherapies for tumors. Cell Mol Immunol 2005;2:331-41
66. Yang XF. Immunology of stem cells and cancer stem cells. Cell Mol Immunol 2007;4:161-71
67. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-8
68. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004;21:137-48
69. Schreiber RD. Cancer vaccines 2004 opening address: the molecular and cellular basis of cancer immunosurveillance and immunoediting. Cancer Immun 2005;5(Suppl 1):1
70. Bifari F, Pacelli L, Krampera M. Immunological properties of embryonic and adult stem cells. World J Stem Cells 2010;2:50-60
71. Ramgolam K, Lauriol J, Lalou C, et al. Melanoma spheroids grown under neural crest cell conditions are highly plastic migratory/invasive tumor cells endowed with immunomodulator function. PLoS One 2011;6:e18784
72. Dillman RO, Nayak SK, Beutel L. Establishing in vitro cultures of autologous tumor cells for use in active specific immunotherapy. J Immunother 1993;14:65-9
73. Nayak SK, Dillman RO. Establishment of multiple tumor cell lines from a patient with melanoma: a simple method to control fibroblast growth. Clin Biotechnol 1991;3:237-42
74. Selvan SR, Carbonell DJ, Fowler AW, et al. Establishment of stable cell lines for personalized melanoma cell vaccine. Melanoma Res 2010;20:280-92
75. Cornforth AN, Fowler AW, Carbonell DJ, et al. Characterization of interferon-gamma-treated melanoma tumor cells for use in dendritic cell-based immunotherapy. Cancer Biother Radiopharm 2011;26:345-51
76. Civenni G, Walter A, Kobert N, et al. Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. Cancer Res 2011;71:3098-109
77. Schlagbauer-Wadl H, Jansen B, Muller M, et al. Influence of MUC18/ MCAM/CD146 expression on human melanoma growth and metastasis in SCID mice. Int J Cancer 1999;81:951-5
78. Kondo T. Stem cell-like cancer cells in cancer cell lines. Cancer Biomark 2007;3:245-50
79. Dillman RO, DePriest C, de Leon C, et al. Patient-specific vaccines derived from autologous tumor cell lines as active specific immunotherapy: results of exploratory phase I/II trials in patients with metastatic melanoma. Cancer Biother Radiopharm 2007;22:309-21
80. Dillman RO, Selvan SR, Schiltz PM, et al. Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific anti-tumor vaccines in patients with metastatic melanoma: final Report. Cancer Biother Radiopharm 2009;24:311-19
81. Dillman RO, Selvan SR, Schlitz PM. Patient-specific dendritic cell vaccines for metastatic melanoma. N Engl J Med 2006;355:1179-81
82. Cornforth AN, Fowler AW, Carbonell DJ, et al. Resistance to the proapoptotic effects of interferon-gamma on melanoma cells used in patient-specific dendritic cell immunotherapy is associated with improved overall survival. Cancer Immunol Immunother 2011;60:123-31
83. Dillman RO, Fogel GB, Cornforth AN, et al. Features associated with survival in metastatic melanoma patients treated with patient-specific vaccines consisting of proliferating autologous tumor cells and autologous dendritic cells. Cancer Biother Radiopharm 2011;26:407-15
84. Dillman RO, Cornforth AN, DePriest C, et al. Tumor stem cell antigens as consolidative active specific immunotherapy: a randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma. J Immunother 2012;35:641-9
85. Dillman RO, Nanci AA, Williams ST, et al. Durable complete response of refractory, progressing metastatic melanoma after treatment with a patient-specific vaccine. Cancer Biother Radiopharm 2010;25:553-7